Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)

Autor:	S. R. Aravind, Kiran P. Singh, Grace Aquitania, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Rok vydání:	2022
Předmět:	Endocrinology Diabetes and Metabolism Internal Medicine
Zdroj:	Diabetes therapy : research, treatment and education of diabetes and related disorders. 13(5)
ISSN:	1869-6953
Popis:	This study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARThis 26-week, open-label, phase 3 trial enrolled 402 people with T1D (n = 105) or T2D (n = 297) previously treated with premix insulin, who were randomized (1:1) to SARAfter 26 weeks, the least squares (LS) mean [median] change in HbA1c from baseline was similar in both treatment groups (SARThe totality of evidence indicates that SAREudraCT number 2017-000092-84.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bebbeff4fe4b05ba639824f46cddc001 https://pubmed.ncbi.nlm.nih.gov/35420397 Zobrazit plný text záznamu Full text from SpringerLink